MedTrace Logo

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00002733 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-05-11

No results posted yet for this study

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.

Conditions

  • Kidney Cancer
  • Melanoma (Skin)
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alfa

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

DRUG

cimetidine

Sponsors & Collaborators

  • Hoag Memorial Hospital Presbyterian

    lead OTHER

Principal Investigators

  • Robert O. Dillman, MD, FACP · Cancer Biotherapy Research Group

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Primary Completion
2000-01-31
Completion
2000-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002733 on ClinicalTrials.gov